Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004202 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004202 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals.
The verdict
NCT00004202, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and RSR13 in treating patients who have stage III non-small cell lung cancer that cannot be removed by surgery.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG chemotherapy
- DRUG efaproxiral
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-10 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004202
The ClinicalTrials.gov registry entry for NCT00004202 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00004202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004202 about?
NCT00004202 is a clinical study titled "Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the...
What is the current status of trial NCT00004202?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-10. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00004202?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), chemotherapy (DRUG), efaproxiral (DRUG).
Who is sponsoring clinical trial NCT00004202?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.